Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer

Abstract Cisplatin‐based chemoradiotherapy is considered standard treatment for unresectable locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with unresectable, radically irradible LA‐NSCLC were r...

Full description

Bibliographic Details
Main Authors: Tsuneo Shimokawa, Kazuhiko Yamada, Hiroshi Tanaka, Kaoru Kubota, Yuichi Takiguchi, Kazuma Kishi, Haruhiro Saito, Yukio Hosomi, Terufumi Kato, Daijiro Harada, Sakiko Otani, Takashi Kasai, Yoichi Nakamura, Toshihiro Misumi, Takeharu Yamanaka, Hiroaki Okamoto
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Cancer Medicine
Subjects:
chemoradiotherapy
cisplatin
docetaxel
locally advanced non‐small‐cell lung cancer
S‐1
Online Access:https://doi.org/10.1002/cam4.3641

Internet

https://doi.org/10.1002/cam4.3641

Similar Items